Document:

Exhibit 4.3

 

THE REGISTERED HOLDER OF THIS UNIT PURCHASE
OPTION BY ITS ACCEPTANCE HEREOF, AGREES THAT THE SECURITIES EVIDENCED BY THIS UNIT PURCHASE OPTION MAY NOT BE SOLD, TRANSFERRED
OR ASSIGNED EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS UNIT PURCHASE OPTION AGREES THAT THE SECURITIES EVIDENCED
BY THIS UNIT PURCHASE OPTION WILL NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED, OR BE THE SUBJECT OF ANY HEDGING,
SHORT SALE, DERIVATIVE, PUT, OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF THIS UNIT PURCHASE
OPTION OR THE SECURITIES EVIDENCED BY THIS UNIT PURCHASE OPTION, FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS FOLLOWING THE EFFECTIVE
DATE (DEFINED BELOW) TO ANYONE OTHER THAN TO ANY MEMBER PARTICIPATING IN THE OFFERING AND THE OFFICERS OR PARTNERS THEREOF, IF
ALL SECURITIES SO TRANSFERRED REMAIN SUBJECT TO THE LOCK-UP RESTRICTION SET FORTH ABOVE FOR THE REMAINDER OF THE TIME PERIOD.

 

UNIT PURCHASE OPTION

 

FOR THE PURCHASE OF [●] UNITS

 

OF ADITX THERAPEUTICS, INC.

 

1. Unit Purchase Option.

 

THIS CERTIFIES THAT,
in consideration of $100.00 duly paid by or on behalf of [  ] (“Holder”), as registered owner of this Unit
Purchase Option, to Aditx Therapeutics, Inc. (the “Company”), Holder is entitled, at any time or from time to time
commencing on the 180th day after the effective date (the “Effective Date”) of the registration statement
(the “Registration Statement”) pursuant to which certain units of securities are offered for sale to the public (the
“Offering”) (the “Commencement Date”), and at or before 5:00 p.m., Eastern Time, on the fifth anniversary
of the Effective Date (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole
or in part, up to [●]1 units (the “Units”) of the Company, each Unit consisting of one share
of the Company’s common stock, par value $0.001 per share (each, a “Share,” and collectively, the “Shares”)
and one warrant to purchase one Share (each a “Warrant,” and collectively, the “Warrants”). Each Warrant
is the same as the warrants included in the Units being registered for sale to the public (the “Public Warrants”)
under the Securities Act of 1933, as amended (the “Act”). If the Expiration Date is a day on which banking institutions
are authorized by law to close, then this Unit Purchase Option may be exercised on the next succeeding day which is not such a
day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action
that would terminate the Unit Purchase Option. This Unit Purchase Option is initially exercisable at $[●] per Unit (or 125%
of the public offering price of the unit of securities being sold in the Offering) so purchased; provided, however, that upon
the occurrence of any of the events specified in Section 5 hereof, the rights granted by this Unit Purchase Option, including
the exercise price per Unit and the number of Units to be received upon such exercise, shall be adjusted as therein specified.
The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.

 

 

1 [Insert 6% of units issued
excluding overallotment]

 

     

     

    

 

2. Exercise.

 

(a) Exercise Procedure.
In order to exercise this Unit Purchase Option, the exercise form attached hereto must be duly executed and completed and delivered
to the Company, together with this Unit Purchase Option and payment of the Exercise Price for the Units being purchased payable
in cash or by certified check or official bank check. If the subscription rights represented hereby shall not be exercised at or
before 5:00 p.m., Eastern time, on the Expiration Date, this Unit Purchase Option shall become and be void without further force
or effect, and all rights represented hereby shall cease and expire.

 

(b) Legend. If required
by applicable law at the time of any exercise, each certificate for the securities purchased under this Unit Purchase Option shall
bear a legend as follows unless such securities have been registered under the Act:

   

“THE SECURITIES
REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR
APPLICABLE STATE LAW. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE ACT AND APPLICABLE STATE LAW.”

 

(c) Cashless Exercise.

 

(i) In lieu of the payment
of the Exercise Price multiplied by the number of Units for which this Unit Purchase Option is exercisable (and in lieu of being
entitled to receive Shares and Warrants) in the manner required by Section 2(a), the Holder shall have the right (but not the obligation)
to convert any exercisable but unexercised portion of this Unit Purchase Option into Units consisting of Shares and Warrants (the
“Conversion Right”) as follows:

 

(A) Upon exercise of
the Conversion Right, the Company shall deliver to the Holder (without payment by the Holder of any of the Exercise Price in cash)
that number of Shares equal to the quotient obtained by dividing (x) the Value of the portion of the Unit Purchase Option being
converted by (y) the Current Market Price of a Share.

 

(B) The “Value”
of the portion of the Unit Purchase Option being converted shall equal the remainder derived by subtracting (a) (i) the Exercise
Price multiplied by (ii) the number of Units underlying the portion of this Unit Purchase Option being converted, from (b) the
Current Market Value of a Unit multiplied by the number of Units underlying the portion of the Unit Purchase Option being converted.

 

    -2-

     

    

 

(C) As used herein, the
term “Current Market Value” per Unit at any date means the remainder derived by subtracting (x) the exercise price
of the Warrants multiplied by the number of Shares issuable upon exercise of the Warrants underlying one Unit from (y) the Current
Market Price of the Shares multiplied by the number of Shares included within one Unit and underlying the Warrants included within
one Unit.

 

(D) The “Current
Market Price” of a Share shall mean (i) if the Shares are listed on a national securities exchange or quoted on the OTCQB
or OTCQX (or any successor exchange or entity), the closing or last sale price of the Shares in the principal trading market for
the Shares on the last trading day preceding the day in question as reported by the exchange, the OTCQB or OTCQX, as the case may
be; (ii) if the Shares are not listed on a national securities exchange or quoted on the OTCQB or OTCQX, but are traded in the
residual over-the-counter market, the closing bid price for the Shares on the last trading day preceding the date in question for
which such quotations are reported in the “Pink Sheets” published by OTC Markets Group, Inc. or similar publisher of
such quotations; and (iii) if the fair market value of the Shares cannot be determined pursuant to clause (i) or (ii) above, such
price as the Board of Directors of the Company shall determine, in good faith.

 

(ii) The Cashless Exercise
Right may be exercised by the Holder on any business day on or after the Commencement Date and not later than the Expiration Date
by delivering the Unit Purchase Option with the duly executed exercise form attached hereto with the cashless exercise section
completed to the Company, exercising the Cashless Exercise Right and specifying the total number of Units the Holder will purchase
pursuant to such Cashless Exercise Right.

 

(d) Resale of Shares.
Holder and the Company acknowledge that as of the date hereof the Staff of the Division of Corporation Finance of the SEC has published
Compliance & Disclosure Interpretation 528.04 in the Securities Act Rules section thereof, stating that the holder of securities
issued in connection with a public offering may not rely upon Rule 144 promulgated under the Act to establish an exemption from
registration requirements under Section 4(a)(1) under the Act, but may nonetheless apply Rule 144 constructively for the resale
of such shares in the following manner: (a) provided that six months has elapsed since the last sale under the registration statement,
an underwriter or finder may resell the securities in accordance with the provisions of Rule 144(c), (e), and (f), except for the
notice requirement; (b) a purchaser of the shares from an underwriter receives restricted securities unless the sale is made with
an appropriate, current prospectus, or unless the sale is made pursuant to the conditions contained in (a) above; (c) a purchaser
of the shares from an underwriter who receives restricted securities may include the underwriter’s holding period, provided
that the underwriter or finder is not an affiliate of the issuer; and (d) if an underwriter transfers the shares to its employees,
the employees may tack the firm’s holding period for purposes of Rule 144(d), but they must aggregate sales of the distributed
shares with those of other employees, as well as those of the underwriter or finder, for a six-month period from the date of the
transfer to the employees. Holder and the Company also acknowledge that the Staff of the Division of Corporation Finance of the
SEC has advised in various no-action letters that the holding period associated with securities issued without registration to
a service provider commences upon the completion of the services, which the Company agrees and acknowledges shall be the closing
of the Offering, and that Rule 144(d)(3)(ii) provides that securities acquired from the issuer solely in exchange for other securities
of the same issuer shall be deemed to have been acquired at the same time as the securities surrendered for conversion (which the
Company agrees is the date of the initial issuance of this Unit Purchase Option). In the event that following a request by Holder
to transfer the Shares in accordance with Compliance & Disclosure Interpretation 528.04 counsel for the Company reasonably
concludes that Compliance & Disclosure Interpretation 528.04 no longer may be relied upon as a result of changes in applicable
laws, regulations, or interpretations of the SEC Division of Corporation Finance, or as a result of judicial interpretations not
known by the Company or its counsel on the date hereof (either, a “Registration Trigger Event”), then the Company shall
promptly, and in any event within five (5) business days following the request, provide written notice to Holder of such determination.
As a condition to giving such notice, the Company shall offer Holder a single “piggyback” registration right pursuant
to an agreement in form reasonably acceptable to the Holder; provided that notwithstanding anything to the contrary, the obligations
of the Company pursuant to this Section 2 shall terminate on the fifth anniversary of the effective date of the Registration Statement
pursuant to which the Offering is being made. In the absence of such conclusion by counsel for the Company, the Company shall,
upon request of Holder given no earlier than six months after the final closing of the Offering, instruct its transfer agent to
permit the transfer of such shares in accordance with Compliance & Disclosure Interpretation 528.04, provided that Holder has
provided such documentation as shall be reasonably be requested by the Company to establish compliance with the conditions of Compliance
& Disclosure Interpretation 528.04. Notwithstanding anything to the contrary, pursuant to FINRA Rule 5110(f)(2)(G)(iv), the
Holder shall not be entitled to more than one “piggyback” registration right hereunder and the duration of the registration
rights hereunder shall not exceed five years from the Effective Date.

 

    -3-

     

    

 

3. Transfer.

 

(a) Restrictions—General. The
securities evidenced by this Unit Purchase Option shall not be sold, transferred, assigned, pledged or hypothecated, or be the
subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition
of, this Unit Purchase Option (or any securities underlying this Unit Purchase Option) for a period of one hundred eighty (180)
days following the Effective Date to anyone other than to any member participating in the offering and the officers or partners
thereof, if all securities so transferred remain subject to the lock-up restriction set forth above for the remainder of the time
period. In order to make any permitted assignment, the Holder must deliver to the Company the assignment form attached hereto duly
executed and completed, together with the Unit Purchase Option and payment of all transfer taxes, if any, payable in connection
therewith. The Company shall within three business days transfer this Unit Purchase Option on the books of the Company and shall
execute and deliver a new Unit Purchase Option or Unit Purchase Options of like tenor to the appropriate assignee(s) expressly
evidencing the right to purchase the aggregate number of Units purchasable hereunder or such portion of such number as shall be
contemplated by any such assignment.

 

(b) Restrictions—Securities. The
securities evidenced by this Unit Purchase Option shall not be transferred unless and until (i) the Company has received the opinion
of counsel for the Holder that the securities may be transferred pursuant to an exemption from registration under the Act and applicable
state securities laws, the availability of which is established to the reasonable satisfaction of the Company, or (ii) a registration
statement or a post-effective amendment to the Registration Statement relating to such securities has been filed by the Company
and declared effective by the Securities and Exchange Commission (the “Commission”) and compliance with applicable
state securities law has been established.

 

    -4-

     

    

 

4. New Unit Purchase Options to be Issued.

 

(a) Partial
Exercise. Subject to the restrictions in Section 3 hereof, this Unit Purchase Option may be exercised or assigned in whole
or in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Unit Purchase Option for cancellation,
together with the duly executed exercise or assignment form and funds sufficient to pay any Exercise Price, the Company shall cause
to be delivered to the Holder without charge a new Unit Purchase Option of like tenor to this Unit Purchase Option in the name
of the Holder evidencing the right of the Holder to purchase the number of Units purchasable hereunder as to which this Unit Purchase
Option has not been exercised or assigned.

 

(b) Loss, Theft,
Destruction. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation
of this Unit Purchase Option and of reasonably satisfactory indemnification or the posting of a bond, the Company shall execute
and deliver a new Unit Purchase Option of like tenor and date. Any such new Unit Purchase Option executed and delivered as a result
of such loss, theft, mutilation or destruction shall constitute a substitute contractual obligation on the part of the Company.

 

5. Adjustments.

 

(a) Exercise
Price and Number of Securities. The Exercise Price and the number of Units underlying the Unit Purchase Option shall be subject
to adjustment from time to time as hereinafter set forth:

 

(i) If after the date
hereof, and subject to the provisions of Section 5(c) below, the number of outstanding Shares is increased by a stock dividend
payable in Shares or by a split-up of Shares or other similar event, then, on the effective date thereof, the number of Shares
underlying each of the Units purchasable hereunder shall be increased in proportion to such increase in outstanding shares. In
such case, the number of Shares, and the exercise price applicable thereto, underlying the Warrants underlying each of the Units
purchasable hereunder shall be adjusted in accordance with the terms of the Warrants. For example, if the Company declares a two-for-one
stock dividend and immediately prior to such dividend this Unit Purchase Option is for the purchase of one Unit at $10.00 per whole
Unit (with each Warrant underlying the Units being exercisable for $12.00 per share), upon effectiveness of the dividend, this
Unit Purchase Option will be adjusted to allow for the purchase of one Unit at $10.00 per Unit, each Unit entitling the holder
to receive two Shares and two Warrants (each Warrant exercisable for $6.00 per share).

 

(ii) If after the date
hereof, and subject to the provisions of Section 5(c), the number of outstanding Shares is decreased by a consolidation, combination
or reclassification of the Shares or other similar event, then, on the effective date thereof, the number of Shares underlying
each of the Units purchasable hereunder shall be decreased in proportion to such decrease in outstanding shares. In such case,
the number of Shares, and the exercise price applicable thereto, issuable upon exercise of the Warrants included in each of the
Units purchasable hereunder shall be adjusted in accordance with the terms of the Warrants. For example, if the Company effects
a one-for-two stock reverse stock split and immediately prior to such stock split this Unit Purchase Option is for the purchase
of one Unit at $10.00 per whole Unit (with each Warrant underlying the Units being exercisable for $12.00 per share), upon effectiveness
of the stock split, this Unit Purchase Option will be adjusted to allow for the purchase of one Unit at $10.00 per Unit, each Unit
entitling the holder to receive 0.5 Shares and 0.5 Warrants (each Warrant exercisable for $24.00 per share).

 

    -5-

     

    

 

(iii) In case of any
reclassification or reorganization of the outstanding Shares other than a change covered by Section 5(a)(i) or 5(a)(ii) hereof
or that solely affects the par value of such Shares, or in the case of any merger or consolidation of the Company with or into
another corporation (other than a consolidation or merger in which the Company is the continuing corporation and that does not
result in any reclassification or reorganization of the outstanding Shares), or in the case of any sale or conveyance to another
corporation or entity of the property of the Company as an entirety or substantially as an entirety in connection with which the
Company is dissolved, the Holder of this Unit Purchase Option shall have the right thereafter (until the expiration of the right
of exercise of this Unit Purchase Option) to receive upon the exercise hereof, for the same aggregate Exercise Price payable hereunder
immediately prior to such event plus the aggregate exercise price of the Shares underlying the Warrants immediately prior to such
event, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification,
reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, by a Holder of the number of
Shares of the Company obtainable upon exercise of this Unit Purchase Option and the underlying Warrants immediately prior to such
event; and if any reclassification also results in a change in Shares covered by Section 5(a)(i) or 5(a)(ii), then such adjustment
shall be made pursuant to Sections 5(a)(i) or 5(a)(ii) and this Section 5(a)(iii). The provisions of this Section 5(a)(iii) shall
similarly apply to successive reclassifications, reorganizations, mergers or consolidations, sales or other transfers.

 

(iv) This form of Unit
Purchase Option need not be changed because of any change pursuant to this Section 5, and Unit Purchase Options issued after such
change may state the same Exercise Price and the same number of Units as are stated in the Unit Purchase Options initially issued
pursuant to this Agreement. The acceptance by any Holder of the issuance of new Unit Purchase Options reflecting a required or
permissive change shall not be deemed to waive any rights to an adjustment occurring after the Commencement Date or the computation
thereof.

 

(b) Substitute
Unit Purchase Option. In case of any consolidation of the Company with, or merger of the Company with, or merger of the
Company into, another corporation (other than a consolidation or merger which does not result in any reclassification or change
of the outstanding Shares), the corporation formed by such consolidation or merger shall execute and deliver to the Holder a supplemental
Unit Purchase Option providing that the holder of each Unit Purchase Option then outstanding or to be outstanding shall have the
right thereafter (until the stated expiration of such Unit Purchase Option) to receive, upon exercise of such Unit Purchase Option,
the kind and amount of shares of stock and other securities and property receivable upon such consolidation or merger, by a holder
of the number of Shares of the Company for which such Unit Purchase Option might have been exercised immediately prior to such
consolidation, merger, sale or transfer. Such supplemental Unit Purchase Option shall provide for adjustments which shall be identical
to the adjustments provided in this Section 5. The above provision of this Section 5 shall similarly apply to successive consolidations
or mergers.

 

    -6-

     

    

 

(c) Fractional
Interests. The Company shall not be required to issue certificates representing fractions of Shares or Warrants upon the
exercise of the Unit Purchase Option, nor shall it be required to issue scrip or pay cash in lieu of any fractional interests,
it being the intent of the parties that all fractional interests shall be eliminated by rounding any fraction up to the nearest
whole number of Warrants, Shares or other securities, properties or rights.

 

6. Reservation and Listing. The
Company shall at all times reserve and keep available out of its authorized Shares, solely for the purpose of issuance upon exercise
of the Warrants underlying the Unit Purchase Option, such number of Shares or other securities, properties or rights as shall be
issuable upon the conversion or exercise thereof. The Company further covenants and agrees that upon exercise of the Warrants underlying
the Unit Purchase Option and payment of the respective Warrant exercise price therefor, all Shares and other securities issuable
upon such exercise shall be duly and validly issued, fully paid and non-assessable and not subject to preemptive rights of any
stockholder. As long as the Unit Purchase Option shall be outstanding, the Company shall use its best efforts to cause all Shares
issuable upon exercise of the Warrants included in the Units issuable upon exercise of the Unit Purchase Option to be listed (subject
to official notice of issuance) on all securities exchanges (or, if applicable on the OTC Bulletin Board or any successor trading
market) on which the Shares issued to the public in connection with the Offering may then be listed and/or quoted.

 

7. Certain Notice Requirements.

 

(a) Right to
Notice. Nothing herein shall be construed as conferring upon the Holders the right to vote or consent as a stockholder
for the election of directors or any other matter, or as having any rights whatsoever as a stockholder of the Company. If, however,
at any time prior to the expiration of the Unit Purchase Option and its exercise, any of the events described in Section 7(b) shall
occur, then, in one or more of said events, the Company shall give written notice of such event at least fifteen days prior to
the date fixed as a record date or the date of closing the transfer books for the determination of the stockholders entitled to
such dividend, distribution, conversion or exchange of securities or subscription rights, or entitled to vote on such proposed
dissolution, liquidation, winding up or sale. Such notice shall specify such record date or the date of the closing of the transfer
books, as the case may be. Notwithstanding the foregoing, the Company shall deliver to each Holder a copy of each notice given
to the other stockholders of the Company with respect to the events enumerated in Section 7(b) at the same time and in the same
manner that such notice is given to all stockholders, even if less than fifteen days.

 

    -7-

     

    

 

(b) Enumerated
Events. The Company shall be required to give the notice described in this Section 7 upon one or more of the following
events: (i) if the Company shall take a record of the holders of its Shares for the purpose of entitling them to receive a dividend
or distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of retained earnings,
as indicated by the accounting treatment of such dividend or distribution on the books of the Company, or (ii) the Company shall
offer to all the holders of its Shares any additional shares of capital stock of the Company or securities convertible into or
exchangeable for shares of capital stock of the Company, or any option, right or warrant to subscribe therefor, or (iii) a dissolution,
liquidation or winding up of the Company (other than in connection with a consolidation or merger) or a sale of all or substantially
all of its property, assets and business shall be proposed.

 

(c) Change
in Exercise Price. The Company shall, promptly after an event requiring a change in the Exercise Price pursuant to Section
5 hereof, send notice to the Holders of such event and change (the “Price Notice”). The Price Notice shall describe
the event causing the change and the method of calculating same and shall be certified as being true and accurate by the Company’s
President and Chief Financial Officer.

 

(d) Notice
Delivery. All notices, requests, consents and other communications under this Unit Purchase Option shall be in writing
and shall be deemed to have been duly made when hand delivered, or mailed by express mail or private courier service: (i) If to
the registered Holder of the Unit Purchase Option, to the address of such Holder as shown on the books of the Company, or (ii)
If to the Company, to the following address or to such other address as the Company may designate by notice to the Holders:

 

Aditx Therapeutics, Inc.

1161 Anderson Street

Suite 105-10014

Loma Linda, CA 92354

Attn: Chief Executive Officer

 

with a copy to (which shall not constitute notice):

 

Sheppard, Mullin, Richter & Hampton LLP

30 Rockefeller Plaza

New York, NY 10112

Attn: Richard A. Friedman

 

8. Reserved.

 

9. Miscellaneous.

 

(a) Amendments. The
Company and Dawson James Securities, Inc. (“Dawson”) may, by means of a signed written instrument, from time to time
supplement or amend this Unit Purchase Option without the approval of any of the Holders in order to cure any ambiguity, to correct
or supplement any provision contained herein that may be defective or inconsistent with any other provisions herein, or to make
any other provisions in regard to matters or questions arising hereunder that the Company and Dawson may deem necessary or desirable
and that the Company and Dawson deem shall not adversely affect the interest of the Holders. All other modifications or amendments
shall require the written consent of and be signed by the party against whom enforcement of the modification or amendment is sought.

 

    -8-

     

    

 

(b) Headings. The
headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning
or interpretation of any of the terms or provisions of this Unit Purchase Option.

 

(c) Entire
Agreement. This Unit Purchase Option (together with the other agreements and documents being delivered pursuant to or
in connection with this Unit Purchase Option) constitutes the entire agreement of the parties hereto with respect to the subject
matter hereof, and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject
matter hereof.

 

(d) Binding
Effect. This Unit Purchase Option shall inure solely to the benefit of, and shall be binding upon, the Holder and the
Company and their permitted assignees, respective successors, legal representative and assigns, and no other person shall have
or be construed to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Unit Purchase
Option or any provisions herein contained.

 

(e) Governing
Law. This Unit Purchase Option shall be governed by and construed and enforced in accordance with the laws of the State
of New York, without giving effect to conflict of laws. The Company hereby agrees that any action, proceeding or claim against
it arising out of, or relating in any way to this Unit Purchase Option shall be brought and enforced in the courts of the State
of New York or of the United States of America for the Southern District of New York, and irrevocably submits to such jurisdiction,
which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts
represent an inconvenient forum. Any process or summons to be served upon the Company may be served by transmitting a copy thereof
by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section
7 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding
or claim. The Company and the Holder agree that the prevailing party(ies) in any such action shall be entitled to recover from
the other party(ies) all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or incurred
in connection with the preparation therefor.

 

(f) Waivers. The
failure of the Company or the Holder to at any time enforce any of the provisions of this Unit Purchase Option shall not be deemed
or construed to be a waiver of any such provision, nor to in any way affect the validity of this Unit Purchase Option or any provision
hereof or the right of the Company or any Holder to thereafter enforce each and every provision of this Unit Purchase Option. No
waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Unit Purchase Option shall be effective
unless set forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought;
and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or
subsequent breach, non-compliance or non-fulfillment.

 

(g) Counterparts. This
Unit Purchase Option may be executed in one or more counterparts, and by the different parties hereto in separate counterparts,
each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and
shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the
other parties hereto. Such counterparts may be delivered by facsimile transmission or other electronic transmission.

 

(h) Exchange
Agreement. As a condition of the Holder’s receipt and acceptance of this Unit Purchase Option, Holder agrees that,
at any time prior to the complete exercise of this Unit Purchase Option by Holder, if the Company and Dawson enter into an agreement
(the “Exchange Agreement”) pursuant to which they agree that all outstanding Unit Purchase Options will be exchanged
for securities or cash or a combination of both, then Holder shall agree to such exchange and become a party to the Exchange Agreement.

 

[Balance of page intentionally left blank]

 

    -9-

     

    

 

IN WITNESS WHEREOF,
the Company has caused this Unit Purchase Option to be signed by its duly authorized officer as of the [●] day of [●],
2020.

 

	 	Aditx Therapeutics, Inc.
	 	 	 
	 	By:	             
	 	Name:	 
	 	Title:	 

 

    -10-

     

    

 

Form To Be Used To Exercise Unit Purchase
Option

 

Aditx Therapeutics, Inc.

1161 Anderson Street

Suite 105-10014

Loma Linda, CA 92354 

 

Attn: Chief Executive Officer

 

Date:        , 2020

 

The undersigned hereby elects irrevocably
to exercise all or a portion of the within Unit Purchase Option and to purchase      Units of Aditx
Therapeutics, Inc., and hereby makes payment of $      (at the rate of $      per
Unit) in payment of the Exercise Price pursuant thereto. Please issue the Shares and Warrants comprising the Units as to which
this Unit Purchase Option is exercised in accordance with the instructions given below.

 

or

 

The undersigned hereby
elects irrevocably to convert its right to purchase Units purchasable under the within Unit Purchase Option by surrender of the
unexercised portion of the attached Unit Purchase Option (with a “Value” based of $      based
on a “Market Price” of $      ). Please issue the securities comprising the Units as
to which this Unit Purchase Option is exercised in accordance with the instructions given below.

 

INSTRUCTIONS FOR REGISTRATION OF SECURITIES

 

	Name:	 	 
	 	(Print in Block Letters)	 
	 	 	 
	Address:	 	 

 

NOTICE: THE SIGNATURE
TO THIS FORM MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE OF THE WITHIN UNIT PURCHASE OPTION IN EVERY PARTICULAR WITHOUT
ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATSOEVER, AND MUST BE GUARANTEED BY A BANK, OTHER THAN A SAVINGS BANK, OR BY A TRUST
COMPANY OR BY A FIRM HAVING MEMBERSHIP ON A REGISTERED NATIONAL SECURITIES EXCHANGE.

 

    -11-

     

    

 

Form To Be Used To Assign Unit Purchase
Option

 

ASSIGNMENT

 

(To be executed by the registered Holder
to effect a transfer of the within Unit Purchase Option)

 

FOR VALUE RECEIVED, does hereby sell, assign
and transfer unto the right to purchase Units of Aditx Therapeutics, Inc., (the “Company”) evidenced by the within
Unit Purchase Option and does hereby authorize the Company to transfer such right on the books of the Company.

 

Dated:     , 2020

 

	 	 
	 	Signature
	 	 
	 	 

 

NOTICE: THE SIGNATURE
TO THIS FORM MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE OF THE WITHIN UNIT PURCHASE OPTION IN EVERY PARTICULAR WITHOUT
ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATSOEVER, AND MUST BE GUARANTEED BY A BANK, OTHER THAN A SAVINGS BANK, OR BY A TRUST
COMPANY OR BY A FIRM HAVING MEMBERSHIP ON A REGISTERED NATIONAL SECURITIES EXCHANGE.

 

 

-12-Exhibit 10.1

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

THIS AGREEMENT is made effective as of the 16th day of June, 2020.

 

AMONG:

 

ZOMEDICA PHARMACEUTICALS INC., a body corporate duly incorporated pursuant
to the laws of the State of Delaware and having an office in the City of Ann Arbor, Michigan (hereinafter referred to as the "Corporation");

 

ZOMEDICA PHARMACEUTICALS CORP., a body corporate duly incorporated pursuant
to the laws of the Province of Alberta and having an office in the City of Ann Arbor, Michigan (hereinafter referred to as the
"Parent")

 

- and -

 

ROBERT COHEN, an individual residing in Eden Prairie, Minnesota, USA (hereinafter
referred to as the "Executive")

 

ARTICLE 1

INTERPRETATION

 

1.1        The phrase "this
Agreement" shall include all terms and provisions of this agreement in writing between the parties hereto, including the recitals.

 

1.2        Wherever in this Agreement
the masculine, feminine or neuter gender is used, it shall be construed as including all genders, as the context so requires; and
wherever the singular number is used, it shall be deemed to include the plural and vice versa, where the context so requires.

 

1.3       Time shall in all respects
be of the essence of this Agreement.

 

1.4        The division of this
Agreement into Articles, Sections and subsections or any other divisions and the inclusion of headings are for convenience only
and shall not affect the construction or interpretation of all or any part hereof.

 

1.5        Each party's rights
may be exercised concurrently or separately and the exercise of any one remedy shall not be deemed an exclusive election of such
remedy or preclude the exercise of any other remedy.

 

ARTICLE 2

TERM OF AGREEMENT

 

2.1        The term of this Agreement
(the "Term") will begin on the date first written above (the "Effective Date") and continue until either the
Corporation or Parent hires a permanent Chief Executive Officer, unless terminated prior to then in accordance with this Agreement.

 

     

     

    

 

ARTICLE 3

EMPLOYMENT OF THE EXECUTIVE

 

3.1        The Corporation wishes
to employ at the Effective Date the Executive as Interim Chief Executive Officer (“Interim CEO”) of the Corporation
and the Parent and the Executive wishes to be employed at the Effective Date by the Corporation on the terms and conditions set
forth herein.

 

3.2        The Executive acknowledges
and agrees that although the Executive will be providing services for the benefit of both the Corporation and the Parent and the
Executive will receive certain benefits from both the Corporation and the Parent under the terms of this Agreement, the Executive’s
employment will be solely with the Corporation and the Corporation will be solely responsible for all employment related obligation
owed to the Executive under this Agreement and any applicable laws.

 

3.3       The Executive shall
report directly to the Parent's Board of Directors (the "Board").

 

3.4       Upon the termination
of the Term, in the event that the Executive has not had his employment terminated by the Corporation for “Cause,”
the Corporation and/or the Parent and the Executive will enter into a transitional consulting agreement for renewable one-year
terms and containing such other terms and conditions as the parties may agree pursuant to which the Executive will agree to provide
certain consulting services upon request as specified therein. As used herein “Cause” shall mean the occurrence or
omission of any event or action which would entitle the Corporation to terminate the employment and offices of the Executive for
cause, and, without limiting the generality of the foregoing, shall include any of the following: (i) failure of the Executive
to substantially perform his duties to the Corporation and the Parent according to the terms of his employment, after notice by
the Corporation or the Parent of the failure to do so and an opportunity for the Executive to correct the same within a reasonable
time from the date of receipt of such notice; or (ii) willful misconduct or gross negligence by the Executive which is materially
injurious to the Corporation and/or the Parent, monetarily or otherwise; or (iii) theft, fraud or misconduct of a kind that involves
a material degree of dishonesty by the Executive and that if publicly disclosed would tend to bring the Corporation and/or the
Parent into disrepute, including (without limitation) the engaging by the Executive in any criminal act of dishonesty resulting
or intended to result directly or indirectly in personal gain of the Executive at the expense of the Corporation and/or the Parent.

 

ARTICLE 4

PERFORMANCE OF DUTIES

 

4.1        The Executive agrees
to devote his business time, attention, skill and efforts to the faithful performance and discharge of his duties and responsibilities
as Interim CEO in conformity with professional standards, in a prudent and workmanlike manner and in a manner consistent with the
obligations imposed under applicable law. The Executive shall promote the interests of the Corporation, the Parent and each other
corporation or other organization which is controlled directly or indirectly by the Corporation and/or the Parent (each an "Affiliate"
and collectively the "Affiliates") in carrying out the Executive's duties and responsibilities and shall not deliberately
and knowingly take any action, or fail to take any action which failure could, or reasonably be expected to, have a material and
adverse effect on the business of the Corporation, the Parent or any of their Affiliates.

 

    -2-

     

    

 

4.2        The Executive discloses,
represents and affirms that he has no obligation toward any person or entity, including former employers, that would be incompatible
with this Agreement or that could create an impediment to or conflict of interest with the performance of his duties hereunder.

 

4.3        The Executive may continue
to sit upon the board of directors of any corporations or organizations on which he serves on the Effective Date as long as the
Board and the Executive mutually agree that his membership on any such board of directors does not unreasonably interfere with
the performance of Executive's duties and responsibilities under this Agreement and, solely with the prior written authorization
of the Chair of the Board, the Executive may serve on any other board of directors.

 

ARTICLE 5

COMPENSATION

 

5.1        Annual Base Salary.
The Corporation shall pay the Executive a base salary (the "Base Salary") which shall be equivalent to THREE HUNDRED
TWENTY FIVE THOUSAND DOLLARS US (US$325,000) on an annualized basis, subject to applicable taxable withholding and deductions and
payable in accordance with the Corporation's standard payroll practice for executive officers.

 

5.2        Cash Bonus.
The Executive shall be eligible to earn a one-time discretionary cash bonus (the "Cash Bonus"), in a target amount equal
to Eighty One Thousand Five Hundred US Dollars (US $81,500). The amount of the Cash Bonus, if any, shall be determined by the Board,
in the good faith exercise of its business judgment, at the end of Executive’s employment with consideration of the achievement
of performance objectives established by the Board and the business performance of the Corporation, the Parent and their Affiliates.
The Cash Bonus, if any, will be payable by the Corporation within sixty (60) days following the termination of Executive's employment.

 

5.3        Business Expenses.
The Corporation shall reimburse the Executive, upon presentation of valid receipts or vouchers, for reasonable entertainment, travel,
telephone and other business expenses (including but not limited to expenses incurred in connection with computer repair/maintenance
and office materials), incurred on behalf of or at the request of the Corporation, the Parent or an Affiliate and which are in
accordance with the Corporation's policies and rules; provided, however: (a) the amount of such expenses eligible for reimbursement
in any calendar year shall not affect the expenses eligible for reimbursement in another calendar year; (b) no right to such
reimbursement may be exchanged or liquidated for another benefit or payment; and (c) any reimbursements of such expenses shall
be made as soon as practicable under the circumstances, but in any event no later than thirty (30) days following the submission
of an expense report and confirming receipts.

 

    -3-

     

    

 

5.4       Benefits. The
Executive shall be entitled to participate in all employee benefit plans made available to other employees of the Corporation,
including health and 401(k) plans, on the same terms as other employees and subject to any qualification period therefor. At the
Executive’s option, the Corporation shall reimburse the Executive for the monthly premiums incurred by the Executive to maintain
his existing health and dental insurance coverage at the current monthly premium rate.

 

ARTICLE 6

VACATION

 

6.1        The Executive shall
be entitled to accrue up to three (3) weeks of paid vacation per calendar year in accordance with the Corporation's vacation policy
for executives.

 

ARTICLE 7

STOCK OPTIONS

 

7.1       Following the execution
of this Agreement, the Board shall grant to Executive options to acquire common shares in the capital of the Parent, with the price
and terms of such options to be set forth in a separate agreement between the Parent and the Executive (the “Option Agreement”).

 

ARTICLE 8

TERMINATION

 

8.1        At-Will Employment.
Nothing in this Agreement shall be construed to alter the at-will employment relationship among the Corporation and the Executive.
Subject to the terms set forth in this Agreement, the Corporation or the Executive may terminate the Executive's employment at
any time for any reason, with or without cause or notice.

 

ARTICLE 9

CONFIDENTIALITY

 

9.1        The Executive acknowledges
that he will receive or conceive, in carrying on or in the course of his work during his employment with the Corporation, confidential
information pertaining to the activities, the technologies, the operations and the business, past, present and future, of the Corporation,
the Parent or their Affiliates or related or associated companies, which information is not in the public domain. The Executive
acknowledges that such confidential information belongs to the Corporation, the Parent and/or their Affiliates and that its disclosure
or unauthorized use could be damaging or prejudicial to the Corporation, the Parent and/or their Affiliates and contrary to their
best interests.

 

    -4-

     

    

 

9.2        Accordingly, the Executive
agrees to respect the confidentiality of such information and not to make use of or disclose it to, or to discuss it with, any
person, other than in the ordinary course of his duties with the Corporation, the Parent and/or their Affiliates, or as required
under applicable law, without the explicit prior written authorization of the Corporation or the Parent.

 

9.3        This undertaking to
respect the confidentiality of such information and not to make use of or disclose or discuss it to or with any person shall survive
and continue to have full effect notwithstanding the termination of the Executive's employment with the Corporation, so long as
such confidential information does not become public as a result of an act by the Corporation, the Parent or a third party, which
act does not involve the fault of one of its executives.

 

9.4        The term confidential
information includes, among other things:

 

(a) products, formulae, processes and composition of products,
as well as raw materials and ingredients, of whatever kind, that are used in their manufacture;

 

(b) technical knowledge and methods, quality control processes,
inspection methods, laboratory and testing methods, information processing programs and systems, manufacturing processes, plans,
drawings, tests, test reports and software;

 

(c) equipment, machinery, devices, tools, instruments and
accessories;

 

(d) financial information, production cost data, marketing
strategies, raw materials supplies, suppliers, staff and client lists and related information, marketing plans, sales techniques
and policies, including pricing policies, sales and distribution data and present and future expansion plans; and

 

(e) research, experiments, inventions, discoveries, developments,
improvements, ideas, industrial secrets and know-how.

 

9.5        The Executive agrees
to keep confidential and not disclose to any third party both the existence and the terms of this Agreement, except if disclosure
is required by applicable law, rule, regulation or the rules of any stock exchange or trading market on which the Parent’s
common shares are then listed or traded. In the event that the Executive is required to disclose the existence or terms of this
Agreement pursuant to subpoena or other duly issued court order, Executive shall give prompt notice to the Corporation and the
Parent of such subpoena or court order to allow the Corporation and/or the Parent sufficient opportunity to contest such subpoena
or court order or to seek an appropriate protective order.

 

9.6        The Executive
acknowledges that he will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure
of a trade secret if (a)  he makes such disclosure in confidence to a Federal, State, or local government official, either
directly or indirectly, or to an attorney and such disclosure is made solely for the purpose of reporting or investigating a suspected
violation of law; or (b) he makes such disclosure in a complaint or other document filed in a lawsuit or other proceeding if such
filing is made under seal.

 

    -5-

     

    

 

ARTICLE 10

NON-COMPETITION

 

10.1        The Executive shall
not compete with the Corporation, the Parent or any of their Affiliates, directly or indirectly. He shall not participate in any
capacity whatsoever in a business that would directly or indirectly compete with the Corporation, the Parent or any of their Affiliates,
including, without limitation, as an executive, director, officer, employer, principal, agent, fiduciary, administrator of another's
property, associate, independent contractor, franchisor, franchisee, distributor or consultant unless such participation is fully
disclosed to the Board and approved in writing in advance. In addition, the Executive shall not have any interest whatsoever in
such an enterprise, including, without limitation, as owner, shareholder, partner, limited partner, lender or silent partner. This
noncompetition covenant is limited as follows:

 

(a)        As to the
time period, to the duration of the Executive's employment and for a period of one (1) years following the date of termination
of his employment;

 

(b)        As to the
geographical area, the territory in which a specific product had been actively exploited by the Corporation, the Parent and/or
their Affiliates during the period of Executive’s employment;

 

(c)        As to the
nature of the activities, to duties or activities which are identical or substantially similar to those performed or carried on
by the Executive at or during Executive’s employment.

 

10.2        The foregoing stipulation
shall nevertheless not prevent the Executive from buying or holding shares or other securities of a corporation or entity other
than the Corporation or the Parent whose securities are publicly traded on a recognized stock exchange where the securities so
held by the Executive do not represent more than five percent (5%) of the voting shares of such other corporation or entity and
do not allow for its control.

 

10.3        The Executive also
undertakes, for the same period and in respect of the same territory referred to hereinabove in subsections 10.1(a), (b) and (c),
not to solicit clients or do anything whatsoever to induce or to lead any person to end, in whole or in part, business relations
with the Corporation, the Parent or any of their Affiliates.

 

10.4        The Executive also
undertakes, for the same period and in respect of the same territory referred to hereinabove in subsections 10.1(a), (b) and (c),
not to induce, attempt to induce or otherwise interfere in the relations which the Corporation, the Parent or any of their Affiliates
has with their distributors, suppliers, representatives, agents and other parties with whom any of them deals.

 

10.5        The Executive also
undertakes, for the same period and in respect of the same territory referred to in subsections 10.1(a), (b) and (c), not to induce,
attempt to induce or otherwise solicit the personnel of the Corporation, the Parent or their Affiliates to leave their employment
with the Corporation, the Parent or any of their Affiliates nor to hire the personnel of the Corporation, the Parent or any of
their Affiliates for any enterprise in which the Executive has an interest.

 

    -6-

     

    

 

10.6        The Executive acknowledges
that the provisions of this Section 10 are limited as to the time period, the geographic area and the nature of the activities
to what the parties deem necessary to protect the legitimate interests of the Corporation, the Parent and their Affiliates, while
allowing the Executive to earn his living.

 

10.7        Nothing in this Section
10 shall operate to reduce or extinguish the obligations of the Executive arising at law or under this contract which survive at
the termination of this Agreement in reason of their nature and, in particular, without limiting the foregoing, the Executive's
duty of loyalty and obligation to act faithfully, honestly and ethically.

 

ARTICLE 11

OWNERSHIP OF INTELLECTUAL PROPERTY

 

11.1        The Executive hereby
assigns and agrees to assign to the Corporation all of his intellectual property rights as of their creation and to make full and
prompt disclosure to the Corporation of all information relating to anything made or designed by him or that may be made or designed
by him during the period of his employment, whether alone or jointly with other persons, or within a period of one (1) years following
the termination of his employment and resulting from or arising out of any work performed by the Executive on behalf of the Corporation,
the Parent or their Affiliates unless specifically released from such obligation in writing by the Corporation's Board of Directors.

 

11.2        In addition, the Executive
renounces all moral rights in any document or work realized during the period of his employment related to his employment by the
Corporation and the Parent. The Executive acknowledges that the Corporation, the Parent and their Affiliates have the right to
use, modify or reproduce any such document or work realized by the Executive, at its entire discretion, without the Executive's
authorization and without his name being mentioned.

 

11.3        At any time during
the period of his employment or after the termination of his employment, the Executive shall sign, acknowledge and deliver, at
the Corporation's expense, but without compensation other than a reasonable sum for his time devoted thereto if his employment
has then terminated, any document required by the Corporation to give effect to Section 11.1, including patent applications and
documents evidencing the assignment of ownership. The Executive shall also provide such other assistance as the Corporation, the
Parent or their Affiliates may require with respect to any proceeding or litigation relating to the protection or defense of intellectual
property rights belonging to the Corporation, the Parent or their Affiliates. The entirety of this Section 11 shall be binding
on the Executive's assignees and legal representatives.

 

    -7-

     

    

 

ARTICLE 12

OWNERSHIP OF FILES AND OTHER PROPERTY

 

12.1        Any property of the
Corporation, the Parent or their Affiliates, including any file, sketch, drawing, letter, report, memorandum or other document,
any equipment, machinery, tool, instrument or other device, any diskette, recording tape, compact disc, software, electronic communication
device or any other property, which comes into the Executive's control or possession during his employment with the Corporation
and the Parent in the performance or in the course of his duties, regardless of whether he has participated in its preparation
or design, how it may have come under his control or into his possession and whether it is an original or a copy, shall at all
times remain the property of the Corporation and the Parent and, upon the termination of the Executive's employment, shall promptly
be returned to the Corporation or its designated representative. The Executive may not keep a copy or give one to a third party
without the prior expressly written permission of the Corporation.

 

ARTICLE 13

ENTIRE AGREEMENT AND TERMINATION OF PRIOR CONTRACTS

 

13.1        This Agreement and
the Option Agreement contain the entire understanding of the parties with respect to the matters contained or referred to herein.
There are no promises, covenants or undertakings by either party hereto to the other, other than those expressly set forth herein
and in the Option Agreement. This Agreement supersedes and replaces any earlier agreement, whether oral or in writing or partly
oral and partly in writing, between the parties hereto, or between any party hereto and the corporate representative of any other
party hereto, respecting the provision of services by the Executive to the Corporation or the Parent.

 

ARTICLE 14

AMENDMENT OF THE AGREEMENT

 

14.1        To be valid and enforceable,
any amendment to this Agreement must be confirmed in writing by each of the parties hereto.

 

ARTICLE 15

NOTICES

 

15.1        Any notice given hereunder
shall be given in writing and sent by registered or certified mail or hand-delivered. If such notice is sent by registered or certified
mail, it shall be deemed to have been received five (5) business days following the date of its mailing if the postal services
are working normally. If such is not the case, the notice must be hand-delivered or served by bailiff, at the discretion of the
sender. In the case of hand-delivery or service, the notice shall be deemed to have been received the same day. It is agreed that
if the delivery date is a non-business day, the notice shall be deemed to have been received on the following business day.

 

15.2        For purposes of mailed
or hand-delivered notices to be effectively delivered under this provision, the notices must be addressed as follows:

 

(a) For the Corporation or the Parent: 100 Phoenix Drive,
Suite 180 Ann Arbor, Michigan 48108.

 

(b) For the Executive: [**]

 

    -8-

     

    

 

ARTICLE 16

SUCCESSORS

 

16.1        This Agreement shall
be binding on the successors, assignees and legal representatives of all of the parties hereto.

 

ARTICLE 17

JURISDICTION

 

17.1        This Agreement shall
be governed by and interpreted in accordance with the laws, including conflicts of laws, by the State of Delaware in the United
States of America. Each of the parties hereby irrevocably attorns to the jurisdiction of the Courts of the State of Delaware with
respect to any matters arising out of this Agreement.

 

ARTICLE 18

SEVERABILITY

 

18.1        If any provision of
this Agreement or the application thereof is held invalid, the invalidity shall not affect other provisions or applications of
this Agreement, which can be given effect without the invalid provisions or applications and, to this end, the provisions of this
Agreement are declared to be severable.

 

ARTICLE 19

MEDIATION

 

19.1        In the event of any
dispute arising under this Agreement, before filing any lawsuit or complaint (except with respect to actions seeking injunctive
relief) the parties shall first attempt to resolve such dispute through voluntary mediation. Any such mediation shall: (1) take
place at a location mutually agreed upon by the parties; and (2) be conducted by a professional mediator mutually agreed upon
by the parties. Each of the parties hereto shall bear their own, respective costs of such mediation; provided, however that each
of the Corporation and the Parent, on the one hand, and the Executive, on the other hand, shall bear one-half the cost of any mediator
appointed by the parties.

 

ARTICLE 20

GENERAL

 

20.1        This Agreement and
the obligations of the Executive hereunder shall not be assigned by either party hereto, in whole or in part, without the prior
consent of the Corporation and the Parent, which consent may be withheld for any reason. The Corporation and the Parent may freely
assign any rights or obligations it may have under this Agreement to any successor or assign.

 

    -9-

     

    

 

21.2        Each party shall do
and perform all such acts and things and execute and deliver all such instruments and documents and writings and give all such
further assurances as may be necessary to give full effect to the provisions and intent of this Agreement.

 

21.3        The Executive agrees
that after termination of employment hereunder for any reason whatsoever, he will tender his resignation from any position he may
hold as an officer or director of the Corporation, the Parent or their Affiliates.

 

21.4        This Agreement shall
inure to the benefit of and be binding upon the Executive and his executors and administrators and upon the Corporation, the Parent
and their respective successors and assigns.

 

21.5        No party can waive
or shall be deemed to have waived any right it has under this Agreement (including any waiver under this section) except to the
extent that such waiver is in writing.

 

ARTICLE 22

COUNTERPARTS

 

22.1        This Agreement may
be executed in counterparts, each of which shall be deemed one and the same Agreement.

 

[Reminder of page intentionally left blank.]

 

 

 

 

 

 

 

 

 

 

    -10-

     

    

 

IN WITNESS WHEREOF the parties have executed this Agreement as of
the date and year first above written.

 

 

	 	 	ZOMEDICA PHARMACEUTICALS, INC.
	 	 	 
	 	 	ZOMEDICA PHARMACEUTICALS CORP.
	 	 	 	 
	 	 	/s/ Jeffrey Rowe	 
	 	 	Jeffrey Rowe	 
	 	 	Chairman of the Board of Directors
	 	 	 	 
	 	 	 	 
	 	 	/s/ Robert Cohen	 
	Witness	 	Robert Cohen	 
	Name:	 	 	 

 

 

 

 

 

 

 

 

 

 

 

 

 

-11-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]